In non-fluke-associated cholangiocarcinoma (most Western CCAs), molecular classification has identified specific clusters enriched with PD-1, PD-L1, and PD-L2 expression signatures [15,54,61], which may derive more significant clinical benefit from durvalumab in combination with gemcitabine and cisplatin [34]. This evidence concerns the gene PDCD1LG2 and cholangiocarcinoma.